HUBILO
2.2.2021 16:20:05 CET | Business Wire | Press release
Event technology company Hubilo has updated its virtual event platform to include support for all the European languages, to meet the demands of a growing global market for virtual events which is expected to be worth over $400bn by 2027.
Hubilo’s platform offers customers a DIY (Do It Yourself) feature that allows them to create events based on individual specifications using a few basic steps, including customizing events in their chosen language to make the entire process simple to understand and operate. The new multilingual feature enables Hubilo to support customers across Europe better, creating a truly universal hub.
Additional Features include a networking lounge where attendees can connect and video chat with the ones with similar interests, virtual booths that provide businesses and promoters with a separate online space to market their products, speaker lounges where attendees can see a list of all event speakers and their sessions and register and add sessions to their event itinerary, live and on-demand sessions, surveys and polls , gamification experiences , automated registrations and ticket processes, and 24/7 customer care services.
For the organizers, there is a provision of features like analytics and insights to help them with quality lead assessments for conversions, a system of records that acts as a reference point to ensure that the organizers have a complete understanding of the attendee engagement rate and interactions along with other required insights across various touchpoints at the event, a broadcast studio which eliminates the need of an additional video conference software, at the same time shares all the tools that are provided by the external software and branded themes , here you can customize your event as per your brand guideline to deliver the precise brand messaging.
Vaibhav Jain, Founder and CEO, Hubilo said: “We launched our virtual platform to deliver a richer online experience for organizers and attendees, mirroring numerous positive features of in-person events along with the addition of a few advanced ones. We are glad that we are able to offer a more inclusive range of languages to our existing, and new as well as prospective clients across Europe. In fact, in order to comply with the European rules and regulations, Hubilo will also now host information on European clients and attendees on dedicated EU servers, within the European jurisdiction.”
Hubilo, which lists Roche, GITEX and Informa Group among its customers, managed to pivot to deliver online virtual events in February 2020, backed by a $4.5m investment led by Lightspeed Venture Partners. Hubilo covers the entire spectrum of meetings, incentives, conferences, and exhibitions (MICE) for external and internal events such as trade fairs, job fairs, award shows, annual sales meet, employee engagement initiatives, town halls, office parties and more.
About Hubilo :
Event technology Company Hubilo has created a comprehensive virtual platform that meets all the event-based requirements through the integration of numerous technology tools. They have redefined the entire marketing landscape around virtual events to unlock massive value for key stakeholders, such as CMOs, event organizers, and sponsors. Hubilo covers the entire spectrum of meetings, incentives, conferences and exhibitions (MICE) which include FMCG, BFSI, Education, Healthcare and Pharmaceutical, Information Technology and Manufacturing, as well as several other industries. Founded in 2015 and pivoted in February 2020 by Vaibhav Jain and Mayank Agarwal, in just 5 years, Hubilo's clientele is inclusive of names like United Nations, Roche, Informa Markets, Tech in Asia, Fortune, AWS, Siemens, GITEX, to name a few.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005812/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom